143 related articles for article (PubMed ID: 24378783)
1. Opening the lead generation toolbox.
Simpson PB; Reichman M
Nat Rev Drug Discov; 2014 Jan; 13(1):3-4. PubMed ID: 24378783
[No Abstract] [Full Text] [Related]
2. Evolving models of collaborative drug discovery: managing intellectual capital assets.
Allarakhia M
Expert Opin Drug Discov; 2018 Jun; 13(6):473-476. PubMed ID: 29569503
[No Abstract] [Full Text] [Related]
3. Are academic drug discovery efforts receiving more recognition with declining industry efficiency?
Bryans JS; Kettleborough CA; Solari R
Expert Opin Drug Discov; 2019 Jul; 14(7):605-607. PubMed ID: 30907161
[No Abstract] [Full Text] [Related]
4. Drug discovery: new models for industry-academic partnerships.
Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
[TBL] [Abstract][Full Text] [Related]
5. COVID has shown the power of science-industry collaboration.
Nature; 2021 Jun; 594(7863):302. PubMed ID: 34135530
[No Abstract] [Full Text] [Related]
6. Lost opportunities.
Phan P; Wong D
Nature; 2017 Dec; 552(7683):S18. PubMed ID: 29220004
[No Abstract] [Full Text] [Related]
7. Patent-free pact pushes the boundaries of precompetitive research.
Dolgin E
Nat Med; 2014 Jun; 20(6):564-5. PubMed ID: 24901552
[No Abstract] [Full Text] [Related]
8. Pharmaceutical pipeline.
Lowen T
Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279
[No Abstract] [Full Text] [Related]
9. Bringing together the academic drug discovery community.
Slusher BS; Conn PJ; Frye S; Glicksman M; Arkin M
Nat Rev Drug Discov; 2013 Nov; 12(11):811-2. PubMed ID: 24172316
[TBL] [Abstract][Full Text] [Related]
10. Pfizer reaches out to academia--again.
Ratner M
Nat Biotechnol; 2011 Jan; 29(1):3-4. PubMed ID: 21221077
[No Abstract] [Full Text] [Related]
11. Partners in discovery.
Fuyuno I
Nature; 2018 Mar; 555(7697):S60. PubMed ID: 29565400
[No Abstract] [Full Text] [Related]
12. Jumping the industrial-academia fence.
Pollastri M
Future Med Chem; 2013 Jan; 5(1):25-6. PubMed ID: 23256810
[No Abstract] [Full Text] [Related]
13. Academic drug discovery: current status and prospects.
Everett JR
Expert Opin Drug Discov; 2015; 10(9):937-44. PubMed ID: 26088126
[TBL] [Abstract][Full Text] [Related]
14. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
Rai AK; Reichman JH; Uhlir PF; Crossman C
Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
[No Abstract] [Full Text] [Related]
15. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
Kaski JC
Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
[No Abstract] [Full Text] [Related]
16. Drug discovery through industry-academic partnerships.
Gray NS
Nat Chem Biol; 2006 Dec; 2(12):649-53. PubMed ID: 17108976
[No Abstract] [Full Text] [Related]
17. Precompetitive consortia in biomedicine--how are we doing?
Mittleman B; Neil G; Cutcher-Gershenfeld J
Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
[No Abstract] [Full Text] [Related]
18. Competition: Unlikely partnerships.
Savage N
Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
[No Abstract] [Full Text] [Related]
19. Medicine. Can intellectual property save drug development?
FitzGerald GA
Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
[No Abstract] [Full Text] [Related]
20. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
Litten RZ; Ryan M; Falk D; Fertig J
Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
